Autologous hematopoietic stem cell transplantation for systemic sclerosis

Area of Science:

• Immunology
• Rheumatology
• Hematology

Background:

• Systemic sclerosis is a rare autoimmune disease characterized by fibrosis, vasculopathy, and inflammation, leading to poor prognosis and high mortality.
• Current therapies, including immunosuppressive drugs, have limited long-term benefits in reversing the disease's natural course.
• Autologous hematopoietic stem cell transplantation (HSCT) has shown potential in early trials for improving skin fibrosis and organ function.

Purpose of the Study:

• To evaluate the efficacy and safety of autologous HSCT in treating severe systemic sclerosis.
• To assess the impact of HSCT on skin fibrosis, organ function, functionality, and quality of life.
• To compare HSCT with standard immunosuppressive therapies in ongoing randomized trials.

Main Methods:

• Phase I/II trials of autologous HSCT in systemic sclerosis patients.
• Ongoing randomized controlled trials: ASSIST, SCOT, and ASTIS comparing HSCT with other treatments.
• Improved pre-transplant evaluation and early disease treatment to reduce treatment-related mortality.

Main Results:

• Early HSCT trials demonstrated reversal of skin fibrosis, improved functionality, and stabilized organ function.
• Significant treatment-related mortality in initial studies was reduced through better patient selection and earlier intervention.
• Ongoing trials are expected to provide definitive data on HSCT's role in severe systemic sclerosis.

Conclusions:

• Autologous HSCT offers a potential therapeutic option for selected patients with severe systemic sclerosis.
• Further results from ongoing randomized trials are crucial to establish HSCT's definitive role.
• Optimizing patient selection and treatment timing is key to maximizing HSCT benefits and minimizing risks.